Metabolically healthy obese and MAFLD: does weight status alone matter? Ziyan PanMohammed Eslam Editorial 17 October 2022 Pages: 1253 - 1255
Platelets in acute liver failure: an innocent bystander or instigator? Rakhi Maiwall Editorial 04 October 2022 Pages: 1256 - 1258
Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle Jules SottyPierre BablonPatrick Soussan Original Article 04 August 2022 Pages: 1259 - 1272
New progress towards elimination of mother-to-child transmission of hepatitis B virus in China Hui ZhengNick WalshFuqiang Cui Original Article 18 October 2022 Pages: 1273 - 1281
Countdown on hepatitis B elimination by 2030: the global burden of liver disease related to hepatitis B and association with socioeconomic status Guiying CaoWenzhan JingMin Liu Original Article 01 September 2022 Pages: 1282 - 1296
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort Yao-Chun HsuDae Won JunMindie H. Nguyen Original Article 07 September 2022 Pages: 1297 - 1307
Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population Hokyou LeeTae Seop LimHyeon Chang Kim Original Article 07 September 2022 Pages: 1308 - 1317
Drug–drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study Vicki Wing-Ki HuiChristopher Langjun AuGrace Lai-Hung Wong Original Article 08 September 2022 Pages: 1318 - 1329
Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma Peng WangAbraham S MosesXiang-jun Han Original Article Open access 25 August 2022 Pages: 1330 - 1338
Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma Linghao ZhaoYuyouye WangWeiping Zhou Original Article Open access 20 September 2022 Pages: 1339 - 1352
A proposal for T1 subclassification in hepatocellular carcinoma: reappraisal of the AJCC 8th edition Chao-Wei LeeHsin-I TsaiHsing-Yu Chen Original Article Open access 28 September 2022 Pages: 1353 - 1367
Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial Lei GuoXubiao WeiShuqun Cheng Original Article 21 October 2022 Pages: 1368 - 1378
Prevention of variceal rebleeding in cirrhotic patients with advanced hepatocellular carcinoma receiving molecularly targeted therapy: a randomized pilot study of transjugular intrahepatic portosystemic shunt versus endoscopic plus β-blocker Yan ChenXuemei MaYongping Yang Original Article 18 October 2022 Pages: 1379 - 1389
Etiology, outcome and prognostic indicators of acute liver failure in Asian children Ruey Terng NgKee Seang ChewWay Seah Lee Original Article 21 September 2022 Pages: 1390 - 1397
Reduction of natural killer cells is associated with poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure Hua-Jie LiNing YangFu-Sheng Wang Original Article 15 September 2022 Pages: 1398 - 1411
Association between metabolically healthy obesity and non-alcoholic fatty liver disease Sailimai ManJun LvHui Liu Original Article 20 August 2022 Pages: 1412 - 1423
Effects of serum branched-chain amino acids on nonalcoholic fatty liver disease and subsequent cardiovascular disease Fei GuoRui ChenWen Hu Original Article 18 July 2022 Pages: 1424 - 1434
Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC Yixiu WangYongfa ZhangLu Wang Original Article 05 September 2022 Pages: 1435 - 1447
The clinical implications of pre-liver transplant diabetes on post-liver transplant outcomes in patients with NASH: analysis of the UNOS database David Uihwan LeeJohn HanNathalie H. Urrunaga Original Article 11 September 2022 Pages: 1448 - 1457
Two-year risedronate treatment for osteoporosis in patients with esophageal varices: a non-randomized clinical trial Lívia Alves Amaral SantosTalles Bazeia LimaFernando Gomes Romeiro Original Article 29 June 2022 Pages: 1458 - 1467
Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials Zhaohui BaiLe WangXingshun Qi Original Article 01 September 2022 Pages: 1468 - 1483
Identification of blood metabolites linked to the risk of cholelithiasis: a comprehensive Mendelian randomization study Jiarui MiLingjuan JiangXiaoyin Bai Original Article 15 June 2022 Pages: 1484 - 1493
Correction to: Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells Muhammad AtifSuz WarnerYe H. Oo Correction 05 September 2022 Pages: 1494 - 1495
Correction to: Infuence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial Amar MukundShakti Prasad ChoudhuryShiv Kumar Sarin Correction 10 October 2022 Pages: 1496 - 1498
